跳至主要内容
临床试验/DRKS00026955
DRKS00026955招募中未知

Assessment of the impact of psychobiotics supplementation on the occurrence of depression and anxiety disorders in people with a history of Covid-19 disease

Department of Pediatric Gastroenterology and Metabolic Diseases; Poznan University of Medical Sciences0 个研究点目标入组 80 人开始时间: 2021年10月25日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 50 Years(—)
性别
All

入选标准

  • Patient-reported postovid depression or anxiety changes (score = 12 on the HADS-anxiety subscale (HADS-A) and / or on the HADS-depression subscale (HADS-D),
  • - consent to participate in the study

排除标准

  • - pregnancy,
  • - severe coexisting diseases (liver cirrhosis, portal hypertension, renal failure, neoplastic diseases, diabetes, connective tissue diseases) and menopause,
  • - previously (pre-covid) diagnosed mental illnesses, psychiatric treatment,
  • - taking psychotropic drugs, stimulating / activating dietary supplements (ginger, guarana, ginseng, melatonin), drugs

研究者

发起方
Department of Pediatric Gastroenterology and Metabolic Diseases; Poznan University of Medical Sciences

相似试验

Assessment of the impact of psychobiotics... | 临床试验